A significant increase in CHK1 levels and activity in tumor cells caused by the silencing of BRD7 enhances tumor cell sensitivity to CHK1 inhibitors, leading to increased cell death via apoptosis, which is reversed by the simultaneous knockdown of CHK1 or USP1. Here, BRD7 is linked to neoplasm.